登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C21H25ClO6
化学文摘社编号:
分子量:
408.87
NACRES:
NA.77
UNSPSC Code:
51111800
MDL number:
产品名称
达格列净, ≥98% (HPLC)
InChI
1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
SMILES string
CCOC1=CC=C(C=C1)CC2=C(C=CC([C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)=C2)Cl
InChI key
JVHXJTBJCFBINQ-ADAARDCZSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D (+7.0° to +13.0°, c = 0.2 in methanol)
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
口服活性,强效和选择性肾钠依赖性葡萄糖共转运蛋白2(SGLT2;SLC5A2)抑制剂,在体内具有降血糖功效。
达格列净(BMS-512148)是一种口服活性、有效和选择性的肾钠依赖性葡萄糖共转运蛋白2(SGLT2;SLC5A2)抑制剂(人/大鼠SGLT2 IC50 = 1.1/3 nM,而人/大鼠SGLT1 IC50 = 1.39/0.6 μM;R-甲基-D-吡喃葡萄糖苷(AMG)摄取测定以及相应的CHO转染子)。达格列净通过防止肾脏葡萄糖重吸收过程并促进尿液中葡萄糖排泄,具有良好的药代动力学特性和口服利用度(口服1 mg/kg和6.6 mg/kg后,在大鼠和狗中分别降低了84%和83%),从而降低了血糖水平(在链脲佐菌素(STZ)诱导的高血糖大鼠中,在口服0.1 mg/kg后5小时降低了55%)体内。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - STOT RE 1
target_organs
Kidney
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
M Obermeier et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(3), 405-414 (2009-12-10)
(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro-2H-pyran-3,4,5-triol (dapagliflozin; BMS-512148) is a potent sodium-glucose cotransporter type II inhibitor in animals and humans and is currently under development for the treatment of type 2 diabetes. The preclinical characterization of dapagliflozin, to allow compound selection and prediction of pharmacological
Wei Meng et al.
Journal of medicinal chemistry, 51(5), 1145-1149 (2008-02-12)
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME
Dapagliflozin - a breakthrough in the search for drugs to treat HFrEF.
Karina Huynh
Nature reviews. Cardiology, 16(12), 700-700 (2019-10-04)
Fengjuan Huang et al.
Frontiers in endocrinology, 10, 441-441 (2019-07-25)
Tubulointerstitial fibrosis (TIF) plays an important role in the progression of renal fibrosis in diabetic nephropathy (DN). Accumulating evidence supports a crucial inhibitory effect of dapagliflozin, a SGLT2 inhibitor, on TIF, but the underlying mechanisms remain largely unknown. This study
Nannan Zhang et al.
Cardiovascular diabetology, 18(1), 107-107 (2019-08-21)
Heart failure with preserved ejection fraction (HFpEF) is a difficult disease with high morbidity and mortality rates and lacks an effective treatment. Here, we report the therapeutic effect of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on hypertension + hyperlipidemia-induced HFpEF in a
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持

